
Inmode Ltd (INMD) Stock Forecast & Price Target
Inmode Ltd (INMD) Analyst Ratings
Bulls say
InMode Ltd demonstrated significant growth in 2Q25, selling 971 systems, contributing to a global installed base of approximately 28,855 units, with 12,347 units located in the U.S., marking a 3.4% increase from the previous quarter. The company also achieved an operating margin of 27.5%, surpassing prior estimates and reflecting a year-over-year improvement of 40 basis points. Moreover, the U.S. domestic sales reached $49.7 million, indicating a robust 9% growth compared to a decline in the previous quarter, underpinning the positive trajectory of the aesthetics market driven by rising consumer and physician interest.
Bears say
InMode Ltd is expected to experience a contraction in its margins, which, while currently among the highest in the med tech sector, signals potential challenges ahead. Furthermore, the company's earnings per share (EPS) growth is forecasted to lag behind revenue growth, indicating a weakening profitability outlook. Additionally, the bear case scenario predicts a revenue compound annual growth rate (CAGR) of less than 5% over the next few years due to slower growth from existing products and limited adoption of new offerings.
This aggregate rating is based on analysts' research of Inmode Ltd and is not a guaranteed prediction by Public.com or investment advice.
Inmode Ltd (INMD) Analyst Forecast & Price Prediction
Start investing in Inmode Ltd (INMD)
Order type
Buy in
Order amount
Est. shares
0 shares